Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases

Brain metastases (BM) are a frequent complication of advanced cancer and are characterized by a variety of neurological symptoms. Although the presence of neurological symptoms is included in the response assessment in patients with primary brain tumors, to the authors' knowledge little is known regarding the prognostic impact of neurological symptoms in patients with BM.

[1]  E. Cho,et al.  CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Tonn,et al.  Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion , 2018, ESMO Open.

[3]  Ying Zhang,et al.  Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[4]  Rafal Dziadziuszko,et al.  Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. , 2017 .

[5]  W. Mason.  NANO, a practical scale for neurologic assessments in patients with brain tumors? , 2017, Neuro-oncology.

[6]  M. Weller,et al.  Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) , 2017, Neuro-oncology.

[7]  Kiwon Lee,et al.  Critical Care Management of Cerebral Edema in Brain Tumors , 2017, Journal of intensive care medicine.

[8]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[9]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[10]  A. Bezjak,et al.  The Brain Metastases Symptom Checklist as a novel tool for symptom measurement in patients with brain metastases undergoing whole-brain radiotherapy. , 2016, Current oncology.

[11]  J. Hainfellner,et al.  Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers , 2016, ESMO Open.

[12]  M. Taphoorn,et al.  Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide , 2015, Journal of Neuro-Oncology.

[13]  M. Mehta,et al.  The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria , 2014, Neuro-oncology.

[14]  C. Vecht,et al.  Seizure prognosis in brain tumors: new insights and evidence-based management. , 2014, The oncologist.

[15]  E. Shaw,et al.  New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. , 2013, Neuro-oncology.

[16]  M. Proescholdt,et al.  Surgical Resection of Brain Metastases—Impact on Neurological Outcome , 2013, International journal of molecular sciences.

[17]  D. Schadendorf,et al.  Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. , 2012, European journal of cancer.

[18]  Daniela Prayer,et al.  Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases , 2012, Clinical & Experimental Metastasis.

[19]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[20]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Brown,et al.  Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. , 2009, International journal of radiation oncology, biology, physics.

[22]  A. Jena,et al.  Magnetic Resonance (MR) Patterns of Brain Metastasis in Lung Cancer Patients: Correlation of Imaging Findings with Symptom , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Martin Klein,et al.  Cognitive deficits in adult patients with brain tumours , 2004, The Lancet Neurology.

[24]  Desmond Curran,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Posner,et al.  Headaches in patients with brain tumors , 1993, Neurology.

[26]  M. Shoykhet,et al.  Emergency Neurological Life Support: Intracranial Hypertension and Herniation , 2017, Neurocritical Care.

[27]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.

[28]  Wade S. Smith,et al.  Emergency Neurological Life Support: Intracranial Hypertension and Herniation , 2012, Neurocritical Care.

[29]  Roy A. Patcheil.  Brain metastases. , 1991, Neurologic clinics.